{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:08:07Z","timestamp":1795172887207,"version":"4.10.3"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.antiviral.2021.105035","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T04:42:08Z","timestamp":1612932128000},"page":"105035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir"],"prefix":"10.1016","volume":"188","author":[{"given":"Mira C.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Chesnokov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliy P.","family":"Mishin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-065X","authenticated-orcid":false,"given":"Juan A.","family":"De La Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natosha","family":"Zanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-980X","authenticated-orcid":false,"given":"David E.","family":"Wentworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa V.","family":"Gubareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2021.105035_bib1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2021.105035_bib2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2021.105035_bib3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/cbdd.13740","article-title":"Methyl brevifolincarboxylate, a novel influenza virus PB2 inhibitor from Canarium Album (Lour.) Raeusch","volume":"96","author":"Chen","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.antiviral.2021.105035_bib4","first-page":"367","article-title":"Replicative fitness of seasonal influenza A viruses with decreased susceptibility to baloxavir","volume":"221","author":"Chesnokov","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib5","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2021.105035_bib6","author":"Clinicaltrialsarenacom"},{"key":"10.1016\/j.antiviral.2021.105035_bib7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","volume":"219","author":"Finberg","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1126\/science.1176225","article-title":"Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans","volume":"325","author":"Garten","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2021.105035_bib9","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1128\/jvi.70.3.1818-1827.1996","article-title":"Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en","volume":"70","author":"Gubareva","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2021.105035_bib10","doi-asserted-by":"crossref","first-page":"1800666","DOI":"10.2807\/1560-7917.ES.2019.24.3.1800666","article-title":"Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016\/17 and 2017\/18 seasons","volume":"24","author":"Gubareva","year":"2019","journal-title":"Euro Surveill."},{"key":"10.1016\/j.antiviral.2021.105035_bib11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2021.105035_bib12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","volume":"71","author":"Hirotsu","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coviro.2014.04.009","article-title":"The epidemiology and spread of drug resistant human influenza viruses","volume":"8","author":"Hurt","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.antiviral.2021.105035_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41564-019-0609-0","article-title":"Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets","volume":"5","author":"Imai","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.antiviral.2021.105035_bib15","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3201\/eid2407.180028","article-title":"Mapping of the US domestic influenza virologic surveillance landscape","volume":"24","author":"Jester","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib16","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/cid\/cit649","article-title":"Outbreak of variant influenza A(H3N2) virus in the United States","volume":"57","author":"Jhung","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib17","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1038\/s41598-019-39276-1","article-title":"Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018","volume":"9","author":"Jorquera","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2021.105035_bib18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3201\/eid1805.111922","article-title":"Human infections with novel reassortant influenza A(H3N2)v viruses, United States, 2011","volume":"18","author":"Lindstrom","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib19","doi-asserted-by":"crossref","first-page":"9385","DOI":"10.1038\/s41598-017-09538-x","article-title":"Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit","volume":"7","author":"Ma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2021.105035_bib20","doi-asserted-by":"crossref","first-page":"10446","DOI":"10.1128\/JVI.01284-16","article-title":"Human monoclonal antibody 81.39a effectively neutralizes emerging influenza A viruses of group 1 and 2 hemagglutinins","volume":"90","author":"Marjuki","year":"2016","journal-title":"J. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2021.105035_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance","volume":"7","author":"McKimm-Breschkin","year":"2013","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.antiviral.2021.105035_bib22","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3201\/eid2510.190607","article-title":"Susceptibility of influenza A, B, C, and D viruses to baloxavir","volume":"25","author":"Mishin","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib23","article-title":"A phase 2 study of pimodivir (JNJ-63623872) in combination with oseltamivir in elderly and NonElderly adults hospitalized with influenza A infection: OPAL study","author":"O'Neil","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1186\/s12864-016-3030-6","article-title":"Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler","volume":"17","author":"Shepard","year":"2016","journal-title":"BMC Genom."},{"key":"10.1016\/j.antiviral.2021.105035_bib25","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.antiviral.2021.105035_bib26","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.1921186117","article-title":"Prevalent Eurasian avian-like H1N1 swine influenza virus with 2009 pandemic viral genes facilitating human infection","volume":"117","author":"Sun","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.antiviral.2021.105035_bib27","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3201\/eid2511.190757","article-title":"Human-to-Human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, february 2019","volume":"25","author":"Takashita","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib28","doi-asserted-by":"crossref","first-page":"104718","DOI":"10.1016\/j.antiviral.2020.104718","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018","volume":"175","author":"Takashita","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2021.105035_bib29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.micinf.2020.05.021","article-title":"Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation","volume":"22","author":"Tian","year":"2020","journal-title":"Microb. Infect."},{"key":"10.1016\/j.antiviral.2021.105035_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3851\/IMP3212","article-title":"Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study","volume":"23","author":"Trevejo","year":"2018","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2021.105035_bib31","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/S0140-6736(17)31274-6","article-title":"Novel influenza A viruses and pandemic threats","volume":"389","author":"Uyeki","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2021.105035_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.7883\/yoken.JJID.2019.210","article-title":"Polymerase acidic subunit I38T mutant influenza A (H3N2) virus isolated from a pediatric patient without prior baloxavir marboxil treatment in Mie Prefecture (November 2018)","volume":"73","author":"Yano","year":"2020","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2021.105035_bib33","article-title":"Mutations in polymerase genes enhanced the virulence of 2009 pandemic H1N1 influenza virus in mice","volume":"7","author":"Zhu","year":"2012","journal-title":"PloS One"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354221000255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354221000255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:33:44Z","timestamp":1759062824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354221000255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":33,"alternative-id":["S0166354221000255"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2021.105035","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2021.105035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105035"}}